sever
acut
respiratori
syndrom
sar
new
emerg
diseas
affect
mani
countri
includ
taiwan
novel
viru
sarsassoci
coronaviru
sarscov
identifi
causal
agent
ksiazek
et
al
peiri
et
al
b
high
fever
myalgia
dri
cough
lymphopenia
characterist
symptom
seen
patient
new
ill
around
case
patient
also
develop
atyp
form
pneumonia
acut
respiratori
distress
result
acut
lung
damag
character
infiltr
chest
radiographi
amongst
chang
observ
lung
sar
patient
epitheli
cell
prolifer
desquam
hyalin
membran
format
along
alveolar
wall
cell
infiltr
lymphocyt
neutrophil
monocyt
earli
stage
diseas
increas
fibrosi
multinucl
epitheli
giant
cell
format
seen
later
stage
chang
seem
indic
exist
twophas
develop
lung
injuri
acut
phase
diffus
alveolar
damag
follow
organ
diffus
alveolar
damag
base
observ
exist
abnorm
excess
inflammatori
respons
lung
hypothes
explain
develop
acut
lung
injuri
inde
patient
still
manifest
lung
injuri
time
viral
load
fall
support
immun
natur
lung
damag
laboratori
find
sar
lymphopenia
thrombocytopenia
elev
lactat
dehydrogenas
creatin
kinas
level
sever
factor
includ
advanc
age
male
sex
high
peak
lactat
dehydrogenas
level
high
peak
creatin
kinas
level
high
initi
absolut
neutrophil
count
signific
predict
factor
intens
care
unit
admiss
death
mortal
sar
report
around
acut
viral
infect
might
produc
damag
host
cell
direct
cytopathi
indirect
immunopatholog
damag
earli
stage
cytopathi
accompani
viral
amplif
antivir
drug
may
import
treatment
later
stage
adapt
immun
respons
mount
viral
clearanc
accompani
sever
inflammatori
damag
especi
high
viral
burden
lung
damag
clearli
understood
intens
inflamm
develop
lung
gener
cytokin
activ
lung
epitheli
cell
undergo
patholog
chang
nichol
et
al
cytokin
storm
involv
patholog
chang
lung
studi
ifngrel
cytokin
chemokin
storm
found
inde
present
sar
patient
level
associ
clinic
manifest
march
august
total
case
defin
probabl
sar
case
base
medic
record
review
retrospect
plu
laboratori
data
epidemiolog
data
sar
advisori
committe
center
diseas
control
cdc
taiwan
sar
expert
committe
nation
health
insur
bureautaiwan
among
patient
rtpcr
confirm
sampl
acut
phase
sera
convalesc
sera
analyz
serum
cytokin
level
epidemiolog
characterist
age
gender
clinic
inform
symptom
underli
diseas
outcom
includ
death
hospit
lengthofstay
well
laboratori
find
hematolog
biochem
arteri
blood
ga
data
collect
medic
chart
record
inform
diseas
investig
webbas
data
report
system
laboratori
cdctaiwan
sarscov
analysi
done
primarili
cdctaiwan
central
laboratori
sarscov
rtpcr
use
defin
infect
primer
use
accord
cdcu
recommend
elisa
immunofluoresc
assay
neutral
test
done
serolog
identif
sarscov
infect
wu
et
al
acut
convalesc
sera
test
parallel
sarscov
sensit
specif
assay
describ
previous
sampl
select
pool
wu
et
al
combin
elisa
immunofluoresc
neutral
test
use
defin
antibodi
sarscov
case
serum
antibodi
sarscov
classifi
ab
posit
group
sera
antibodi
classifi
ab
neg
group
cytokin
level
determin
either
bd
human
cytokin
chemokin
bead
array
cba
kit
bd
human
cytokin
cba
kit
bd
pharmingen
san
diego
ca
use
measur
tnfa
ifng
protein
level
flow
cytometri
particlebas
immunoassay
kit
allow
simultan
measur
six
cytokin
ml
sampl
use
ml
sampl
critic
preciou
patient
serum
sampl
routin
use
cba
kit
quantit
cytokin
level
patient
variou
diseas
hung
et
al
assay
perform
accord
instruct
manufactur
limit
detect
immunoassay
pgml
pgml
pgml
pgml
pgml
tnfa
pgml
ifng
bd
human
chemokin
cba
kit
use
measur
mig
rant
protein
level
flow
cytometri
particlebas
immunoassay
kit
allow
simultan
measur
five
chemokin
ml
sampl
limit
detect
immunoassay
pgml
pgml
rant
pgml
mig
pgml
pgml
tgfb
stnfri
tnfa
detect
elisa
kit
biosourc
camarillo
ca
detect
limit
pgml
stnfri
pgml
tgfb
pgml
tnfa
detect
wit
elisa
kit
mbl
medic
biolog
laboratori
co
nagoya
japan
r
system
inc
minneapoli
mn
respect
detect
limit
pgml
pgml
cytokin
clinic
laboratori
data
antibodi
posit
antibodi
neg
group
death
surviv
group
compar
student
ttest
sigmaplot
softwar
spss
inc
chicago
il
p
taken
signific
use
cba
cytokin
chemokin
kit
elisa
cytokin
chemokin
includ
ifng
tnfa
tgfb
mig
rant
well
tnfri
analyz
shown
figur
total
rtpcrconfirm
sar
patient
high
level
ifng
tgfb
found
sera
sar
patient
chemokin
mig
also
elev
mean
valu
ifng
tgfb
mig
pgml
respect
serum
level
cytokin
vari
great
deal
differ
individu
highli
elev
acut
phase
post
sarscov
infect
significantli
differ
normal
healthi
control
cytokin
return
normal
level
convalesc
phase
day
later
post
diseas
onset
tabl
contrast
cytokin
tnfa
tnfri
low
undetect
among
detect
cytokin
ifng
relat
chemokin
especi
promin
patient
detect
ifng
serum
patient
ifng
level
higher
pgml
higher
pgml
ifngstimul
chemokin
mig
also
highli
elev
cytokin
profil
sar
compar
viral
diseas
name
enteroviru
induc
pulmonari
edema
dengu
virusinduc
dengu
hemorrhag
feverdengu
shock
syndrom
amount
ifng
observ
sar
patient
four
sixfold
higher
pulmonari
edema
pe
dengu
virusinduc
dengu
hemorrhag
fever
dhf
hung
et
al
mean
valu
ifng
pulmonari
edema
patient
dengu
hemorrhag
fever
patient
pgml
respect
fig
surprisingli
level
low
patient
serum
level
lower
pgml
contrast
pulmonari
edema
dengu
hemorrhag
fever
mean
concentr
pulmonari
edema
dengu
hemorrhag
fever
pgml
respect
multipl
cytokin
detect
simultan
cba
kit
therefor
ifng
individu
plot
hisher
reciproc
relationship
ifng
found
individu
fig
relationship
also
found
mig
data
shown
pattern
differ
pulmonari
edema
dengu
virusinduc
dengu
hemorrhag
fever
two
diseas
mix
ifng
present
simultan
regard
cytokin
present
sar
pulmonari
edema
dengu
hemorrhag
fever
fig
e
sar
patient
detect
level
higher
detect
limit
pgml
fig
contrari
markedli
elev
pulmonari
edema
patient
play
import
role
pulmonari
edema
post
infect
understand
cytokin
profil
development
process
sar
post
sarscov
infect
rtpcrconfirm
case
divid
two
categori
base
antibodi
statu
shown
tabl
ii
mean
age
patient
ab
group
significantli
higher
patient
ab
group
larger
percentag
male
femal
found
ab
group
hand
larger
percentag
femal
male
found
ab
group
mortal
also
significantli
higher
ab
ab
group
durat
stay
hospit
reflect
mortal
rate
therefor
lower
ab
ab
group
laboratori
data
blood
urin
nitrogen
white
blood
count
complet
blood
count
differ
two
group
tgfb
mig
also
significantli
differ
two
group
highli
elev
differ
ifng
level
serum
ifng
level
ab
group
significantli
higher
ab
group
tabl
ii
understand
kinet
chang
cytokin
earli
stage
acut
infect
level
ifng
mig
tgfb
ab
group
plot
day
post
fever
onset
fig
ifng
relat
chemokin
mig
alreadi
highli
elev
earli
day
ifng
mig
seem
appear
earliest
peak
day
post
fever
onset
increas
later
peak
day
post
fever
onset
tgfb
also
appear
later
delin
relationship
ifng
relat
cytokin
linear
regress
ifng
mig
analyz
good
associ
found
mig
correl
coeffici
r
mig
respect
fig
associ
better
fig
comparison
ifng
sar
pulmonari
edema
dengu
virusinduc
dengu
hemorrhag
fever
serum
cytokin
level
sar
pulmonari
edema
dengu
hemorrhag
fever
patient
compar
ifng
b
c
e
reciproc
relationship
ifng
shown
sar
patient
f
bar
repres
mean
valu
cytokin
n
patient
serum
sampl
determin
ifng
contrari
reciproc
relationship
exist
ifng
relat
chemokin
low
produc
cytokin
pattern
ab
group
obviou
ab
group
data
shown
seem
ifng
mig
activ
togeth
earli
phase
sarscov
acut
infect
sinc
sarscov
infect
fatal
intens
inflammatori
respons
involv
diseas
process
compar
cytokin
death
surviv
case
sar
patient
shown
tabl
iii
mean
age
death
group
older
surviv
group
death
group
also
higher
blood
urin
nitrogen
aspar
aminotransferas
valu
surviv
group
sarscovinfect
patient
underli
diseas
suscept
death
cytokin
mig
level
significantli
higher
surviv
group
seem
also
higher
death
group
surviv
group
p
valu
statist
signific
mig
chemokin
activ
cell
chemokin
neutrophil
suggest
extens
inflamm
probabl
respons
inflammatori
respons
lung
sar
fatal
case
surviv
group
ifng
plot
circul
lymphocyt
count
monocyt
count
sar
patient
invers
associ
found
lymphocyt
monocyt
count
correl
coeffici
r
respect
fig
invers
associ
also
found
ifng
circul
lymphocyt
count
howev
pattern
differ
neutrophil
posit
associ
occur
circul
neutrophil
count
paramet
posit
associ
exist
tgfb
durat
stay
hospit
surviv
group
fig
tgfb
detect
patient
appear
late
post
infect
gener
serum
level
posit
associ
durat
stay
hospit
surviv
group
correl
coeffici
cytokin
pattern
death
group
obviou
surviv
group
data
shown
base
data
conclud
interferongrel
cytokin
storm
sarscov
infect
cytokin
probabl
involv
inflammatori
respons
damag
host
sar
outbreak
taiwan
sera
either
suspect
probabl
case
sent
cdctaiwan
offici
final
diagnosi
sarscov
infect
therefor
studi
sera
analyz
firsttim
point
collect
hospit
immunomodul
steroid
intraven
immunoglobulin
ribavirin
given
patient
blood
collect
rtpcrconfirm
case
use
crosssect
studi
firsttim
point
treatment
acut
phase
stage
analyz
sera
collect
convalesc
phase
also
determin
cytokin
level
return
basal
level
sequenti
serum
sampl
avail
examin
kinet
chang
cytokin
individu
diseas
progress
patient
pool
plot
day
post
fever
onset
found
high
elev
ifng
relat
cytokin
chemokin
serum
level
ifng
mig
alreadi
high
even
day
fever
onset
strong
bia
product
toward
ifng
differ
pulmonari
edema
dengu
virusinduc
dengu
hemorrhag
fever
reciproc
relationship
exist
individu
ifng
overproduct
inflammatori
ifng
chemokin
might
result
lack
downregul
immun
respons
sarscov
infect
ifng
inflammatori
cytokin
possess
mani
biolog
activ
barber
liu
et
al
enhanc
major
histocompat
complex
express
activ
macrophag
function
stimul
chemokin
product
induc
apoptosi
arrest
cell
cycl
enhanc
fa
express
ifng
primarili
produc
nk
cell
cell
macrophag
product
upregul
andor
chemokin
mig
found
markedli
elev
acut
stage
sar
patient
level
extrem
high
seem
reliabl
marker
viral
infect
report
respiratori
syncyti
viru
miller
et
al
influenza
viru
ishiguro
et
al
fig
associ
ab
sar
patient
serum
chemokin
mig
level
ab
group
sar
patient
plot
ifng
individu
linear
regress
associ
correl
analyz
former
number
repres
correl
coeffici
latter
r
cinatl
et
al
directli
induc
either
viralinfect
epitheli
cell
ifng
stimul
therefor
correl
level
ifng
strong
stronger
associ
exist
chemokin
mig
howev
sarscovinduc
chemokin
product
lung
without
concomit
product
inflammatori
cytokin
probabl
would
caus
lung
patholog
chang
sarscovinfect
mice
glass
et
al
detect
anoth
chemokin
rant
upperlimit
cba
kit
pgml
normal
healthi
control
sar
patient
unfortun
sera
dilut
determin
exact
concentr
limit
amount
patient
sera
ifng
stimul
lung
epitheli
cell
line
produc
chemokin
includ
rant
unpublish
observ
therefor
rant
suppos
also
elev
sar
infect
chemokin
recruit
activ
cell
lung
sever
report
cytokin
level
sar
patient
proinflammatori
cytokin
tnfa
increas
acut
stage
sarscov
infect
pang
et
al
ng
et
al
wong
et
al
zhang
et
al
studi
neither
tnfa
tnfri
detect
might
relat
time
sampl
collect
use
corticosteroid
intraven
immunoglobulin
ribavirin
treat
sar
patient
would
modul
cytokin
product
sera
test
firsttim
point
collect
hospit
patient
treat
immunomodul
lung
patholog
studi
shown
intens
lymphocyt
infiltr
sar
patient
ifng
alreadi
highli
induc
earli
ab
stage
even
higher
late
ab
stage
although
ifna
b
report
inhibit
vitro
replic
sarscov
protect
type
pneumocyt
sarscov
infect
macaqu
haagman
et
al
tan
et
al
interferon
especi
ifng
doubleedg
sword
bia
ifng
relat
chemokin
product
might
respons
abnorm
inflammatori
respons
sar
patient
ifngrel
cytokin
storm
induc
post
sarscov
infect
antibodi
respons
sarscov
antigen
delay
sarscov
infect
detect
week
later
peiri
et
al
ab
group
repres
earli
stage
acut
sarscov
infect
shown
earli
time
sera
collect
fever
onset
figur
elder
weak
immun
respons
also
includ
categori
base
antibodi
distinct
factor
age
gender
mortal
durat
stayinhospit
significantli
differ
two
group
older
male
high
mortal
young
femal
seem
strong
immun
respons
higher
ifng
product
consist
risk
factor
analysi
surviv
death
group
mig
level
higher
death
surviv
group
seem
male
older
patient
higher
chemokin
product
underli
diseas
suscept
death
post
sarscov
infect
sar
lung
caus
intens
chemokineinduc
activ
cellmedi
inflamm
might
fatal
neutrophil
inflamm
probabl
also
involv
surviv
sar
patient
invers
relationship
ifng
lymphocyt
monocyt
count
interest
lymphopenia
common
sar
patient
lymphopenia
occur
clearli
understood
ifng
report
induc
apoptosi
activ
cell
bernabei
et
al
sobek
et
al
two
possibl
reason
sequestr
lung
bchemokinerecruit
lymphocyt
ifnginduc
apoptosi
neutrophil
posit
associ
found
neutrophil
count
neutrophil
achemokin
also
elev
neutrophil
recruit
lung
enhanc
lung
damag
tgfb
found
increas
sarscov
infect
patient
detect
serum
tgfb
late
stage
tgfb
level
significantli
differ
death
surviv
group
tgfb
level
plot
clinic
data
patient
interest
find
posit
associ
tgfb
amount
durat
stayinhospit
individu
surviv
fibrosi
sequela
post
sarscov
infect
individu
tgfb
induc
prolifer
fibroblast
krein
winston
dhainaut
et
al
therefor
high
product
tgfb
might
involv
develop
fibrosi
dexamethason
intraven
immunoglobulin
use
treat
sar
patient
benefici
fig
associ
ifng
tgfb
clinic
manifest
sar
surviv
patient
serum
chemokin
ifng
level
surviv
sar
patient
plot
circul
lymphocyt
count
monocyt
count
neutrophil
count
individu
analysi
tgfb
durat
stayinhospit
patient
n
detect
tgfb
determin
linear
regress
associ
correl
analyz
former
number
repres
correl
coeffici
latter
r
effect
although
effect
debat
recent
et
al
dexamethason
known
inhibit
cytokin
product
delay
chemokinerecruit
inflamm
immunoglobulin
modul
cytokin
overact
inhibit
lymphocyt
macrophag
activ
ifng
cytokin
storm
induc
respons
immunolog
damag
host
reason
benefici
effect
probabl
due
interfer
ifng
cytokin
storm
report
ifng
alon
combin
activ
fa
pathway
induc
apoptosi
lung
epitheli
cell
ifng
ifng
plu
antifasinduc
apoptosi
could
block
dexamethason
wen
et
al
